IL17A and psoriasis: However, reports that the treatment of psoriasis using IL-12–IL-23 blockade27,28 or IL-17 blockade29 in patients without overt joint symptoms resulted in suppression of these sonographic and radiological abnormalities are promising and will surely aid in the design of future preventive studies, particularly if paired with clinical and molecular risk factor enrichment strategies.